Skip to main content
Springer Nature Link
Log in

Zoster Vaccine (Zostavax®)

A Review of its Use in Preventing Herpes Zoster and Postherpetic Neuralgia in Older Adults

  • Adis Drug Evaluation
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Individuals who have been infected with varicella zoster virus (VZV) are at risk for developing herpes zoster and this risk appears to be related to a decline in VZV-specific cell-mediated immunity (CMI). Zostavax® (zoster vaccine) is a one-dose, high-potency, live, attenuated VZV vaccine that boosts VZV-specific CMI and this is its presumed mechanism of action. Zoster vaccine is registered in the EU for use in adults aged ≥50 years for the prevention of herpes zoster and herpes zoster-related postherpetic neuralgia.

In the Shingles Prevention Study, a placebo-controlled trial in adults aged ≥60 years (n = 38 546), zoster vaccine led to a sustained boost of VZV-specific CMI. Over a mean herpes zoster surveillance period of 3.1 years, zoster vaccine reduced the herpes zoster-related burden of illness by 61%, reduced the incidence of herpes zoster by 51% and reduced the incidence of postherpetic neuralgia by 67%. Zoster vaccine recipients who developed herpes zoster had a shorter illness duration and severity than placebo recipients who developed herpes zoster. Zoster vaccine had continuing efficacy in a Shingles Prevention Study sub-population followed for 7 years post-vaccination. Zoster vaccine was generally well tolerated in older adults. While cost-effectiveness estimates in pharmaco-economic analyses varied widely according to vaccine and herpes zoster parameter cost/benefit estimates, an analysis from a UK perspective found a zoster vaccine immunization programme in adults aged 65 years to be cost effective. In older adults, the zoster vaccine has the potential to significantly reduce the herpes zoster burden of illness by decreasing the incidence of herpes zoster or reducing its severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Table I
Fig. 4
Table II

Similar content being viewed by others

References

  1. Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008 Dec; 25(12): 991–1006

    Article  PubMed  CAS  Google Scholar 

  2. Araújo LQ, MacIntyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes 2007; 14Suppl. 2: 40A–4A

    Google Scholar 

  3. Schmader K, Gnann Jr JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008 Mar 1; 197Suppl. 2: S207–15

    Article  PubMed  Google Scholar 

  4. Van Hoek AJ, Gay N, Melegaro A. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9): 1454–67

    Article  PubMed  Google Scholar 

  5. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197Suppl. 2: s237-41

    Google Scholar 

  6. Johnson RW, Rice ASC. Pain following herpes zoster: the influence of changing population characteristics and medical developments. Pain 2007; 128(1–2): 3–5

    Article  PubMed  Google Scholar 

  7. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197(6): 825–35

    Article  PubMed  CAS  Google Scholar 

  8. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009 Jan; 137(1): 38–47

    Article  PubMed  CAS  Google Scholar 

  9. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32(10): 1481–6

    Article  PubMed  CAS  Google Scholar 

  10. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Databse Syst Rev 2009 Apr 15; (2): CD006866

    Google Scholar 

  11. Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22(5): 417–42

    Article  PubMed  CAS  Google Scholar 

  12. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24(9): 1308–14

    Article  PubMed  Google Scholar 

  13. European Medicines Agency. Zostavax: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/zostavax/H-674-PI-en.pdf [Accessed 2009 Jul 1]

  14. Merck. Varivax®: prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/v/varivax_pi.pdf [Accessed 2009 Mar 4]

  15. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22): 2271–84 plus supplementary material available from http://content.nejm.org/cgi/content/full/352/22/2271/DC1

    Article  PubMed  CAS  Google Scholar 

  16. Schmader K, Oxman MN, Levin M, et al. Persistence of zoster vaccine efficacy [abstract no. G-409 plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC

  17. Oxman MN, Williams HM, Levin MJ, et al. The impact of age on the efficacy of zoster vaccine [poster]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–8; San Francisco (CA)

  18. Oxman MN, Williams HM, Levin MJ, et al. Efficacy of zoster vaccine according to dermatome region [abstract no.2699 plus poster]. 45th Annual Meeting of the Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 15–18; Washington, DC

  19. Schmader K, Saddier P, Johnson G, et al. The effect of zoster vaccine on interference of herpes zoster with activities of daily living (ADL) [poster]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–8; San Francisco (CA)

  20. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia (Shingles Prevention Study Group). J Infect Dis 2008 Mar 1; 197Suppl. 2: 228–36

    Article  Google Scholar 

  21. Robinson DM, Perry CM. Zoster vaccine live (Oka/Merck). Drugs Aging 2006; 23(6): 525–31

    Article  PubMed  Google Scholar 

  22. Levin MJ, Murray M, Rotbart HA, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166: 253–9

    Article  PubMed  CAS  Google Scholar 

  23. Levin MJ, Murray M, Zerbe GO, et al. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994 Sep; 170: 522–6

    Article  PubMed  CAS  Google Scholar 

  24. Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998 Nov; 178Suppl. 1: 109–12

    Article  Google Scholar 

  25. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200(7): 1068–77

    Article  PubMed  CAS  Google Scholar 

  26. Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immuno-genicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 2008; 15(2): 314–9

    Article  PubMed  CAS  Google Scholar 

  27. Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55(10): 1499–507

    Article  PubMed  Google Scholar 

  28. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old [abstract no.G-399d plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC

  29. Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and adults 60 years and older. Clin Vaccine Immunol 2009 May; 16(5): 646–52

    Article  PubMed  CAS  Google Scholar 

  30. Mills R, Tyring S, Lawless J et al. Safety, tolerability and immunogenicity of zoster vaccine in subjects with a history of herpes zoster (HZ) [abstract no. G-407 plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DC

  31. Schmader KE, Bobrove AM, Levin MJ, et al. Immunogenicity & safety of varicella-zoster virus (VZV) vaccine administered to older adults with or without diabetes mellitus (DM) or chronic obstructive pulmonary disease (COPD) [abstract no. D26 plus poster]. 2006 American Geriatrics Society Annual Meeting; 2006 May 3–7; Chicago (IL)

  32. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145(5): 317–25

    PubMed  Google Scholar 

  33. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25(49): 8326–37

    Article  PubMed  Google Scholar 

  34. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007 May 15; 44(10): 1280–8

    Article  PubMed  Google Scholar 

  35. Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4(3): 238–45

    Article  PubMed  Google Scholar 

  36. Najafzadeh M, Marra CA, Galanis E, et al. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27(12): 991–1004

    Article  PubMed  Google Scholar 

  37. Merck. Zostavax®: prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf [Accessed 2009 Mar 4]

  38. Merck Frosst. Zostavax™ approved in Canada: the first and only vaccine for the prevention of shingles [media release] 2008 Aug 28 [online]. Available from URL: http://www.merckfrosst.com

  39. Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Pub Health 2008; 99(5): 383–6

    Google Scholar 

  40. Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007 Mar 1; 25(11): 2139–44

    Article  PubMed  CAS  Google Scholar 

  41. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008 Jun; 57(RR-5): 1–30

    PubMed  Google Scholar 

  42. Chidiac C, Bruxelle J, Daures J-P, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001 Jul 1; 33: 62–9

    Article  PubMed  CAS  Google Scholar 

  43. Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18: 2915–20

    Article  PubMed  CAS  Google Scholar 

  44. Gnann Jr JW. Vaccination to prevent herpes zoster in older adults. J Pain 2008 Jan; 9(1 Suppl. 1): S31–6

    PubMed  CAS  Google Scholar 

  45. Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008 Jan; 26(3): 235–49

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Mark Sanford & Gillian M. Keating

Authors
  1. Mark Sanford
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Mark Sanford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanford, M., Keating, G.M. Zoster Vaccine (Zostavax®). Drugs Aging 27, 159–176 (2010). https://doi.org/10.2165/10489140-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/10489140-000000000-00000

Keywords